Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark ...

Tempus AI just acquired Ambry Genetics, a well-known leader in genetic testing, for $600 million, which includes $375 million in cash payments and $225 million in shares.

The healthcare technology space is gaining enormous investors' attention these days, thanks to the rapid advancements in artificial intelligence (AI) in this niche. Companies like Tempus AI TEM are ...

The company recently completed its acquisition of Ambry Genetics, providing Tempus AI with the ability to offer patients more comprehensive cancer screening with Ambry's hereditary cancer assay.

Tempus AI leverages AI for treatment decisions and diagnostics, thriving in the booming healthcare AI market with strong ...

Tempus AI started off the year with a stellar rally, but then bounced back from its peak in early February. There's no way this stock will remain cheap for long. Tempus AI's financials have ...

Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, reflecting confidence in the growth potential of the tech company that ...

Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest since its successful IPO in June 2024. The stock had been on a strong ...

Refusing to slow down since the start of the new year, shares of TempusAI (NASDAQ: TEM) have skyrocketed nearly 99% since Jan. 1. In light of the artificial intelligence (AI) stock's strong ...